Cepheid Overview
Pro stress-test →Cepheid is a molecular diagnostics company owned by Danaher Corporation that develops, manufactures, and markets fully-integrated systems for genetic analysis. The company's GeneXpert platform automates sophisticated molecular testing across clinical, industrial, and biothreat markets, enabling rapid detection of infectious diseases and genetic conditions from diverse sample types.
Strategic Profile
Pro stress-test →Cepheid leverages automation and ease-of-use as core competitive advantages, reducing manual laboratory procedures and enabling decentralized testing. As a Danaher subsidiary since 2016, it benefits from parent company scale and resources while focusing on expanding its molecular diagnostics portfolio, including recent CE marking achievements for gastrointestinal pathogen detection panels.
Competitive Landscape
Pro stress-test →Cepheid competes in molecular diagnostics against companies like Bio-Rad, BioMérieux, Qiagen, and Abbott Diagnostics. Its competitive advantage rests on the automated, easy-to-use GeneXpert platform ecosystem, which reduces manual steps and enables rapid results. Competitors typically emphasize throughput, multiplex capacity, or laboratory automation, while Cepheid targets decentralized, rapid testing across diverse clinical settings.
Industry Context
Cepheid operates in Molecular diagnostics systems.
Key facts
Founded: 1996 · Headquarters: Sunnyvale, US · Employees: Unknown · Revenue: Estimated $800M-$1B (subsidiary of Danaher; standalone figures unavailable post-delisting) · Market cap: N/A